Cargando…

The effects of CYP24A1 on clinicopathological features and the prognosis of pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a type of exocrine pancreatic cancer that presents itself in the form of a highly malignant tumor. However, in the past few decades, with breakthroughs in the diagnosis and treatment of malignant tumors, there have yet to be satisfactory results...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Wei, Wang, Teng-Fei, Yi, Wen, Tong, Wei-Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798510/ https://www.ncbi.nlm.nih.gov/pubmed/35117813 http://dx.doi.org/10.21037/tcr.2020.02.78

Ejemplares similares

Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression
por: Park, Sejun, et al.
Publicado: (2023)

Differential expression of RBM5 and KRAS in pancreatic ductal adenocarcinoma and their association with clinicopathological features
por: PENG, JIE, et al.
Publicado: (2013)

Effect of Perioperative CEA and CA24-2 on Prognosis of Early Resectable Pancreatic Ductal Adenocarcinoma
por: Li, Xiaojie, et al.
Publicado: (2020)

Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma
por: Zhang, Yalu, et al.
Publicado: (2021)

Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma
por: Matsushita, Katsunori, et al.
Publicado: (2021)

Pancreatic Ductal Adenocarcinoma: Relating Biomechanics and Prognosis
por: MacCurtain, Benjamin M., et al.
Publicado: (2021)

Subpopulations of cancer-associated fibroblasts link the prognosis and metabolic features of pancreatic ductal adenocarcinoma
por: Hu, Beiyuan, et al.
Publicado: (2022)

Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma
por: Yang, Jian-Yu, et al.
Publicado: (2015)

Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival
por: Pergolini, Ilaria, et al.
Publicado: (2017)

Down-expression of CD36 in pancreatic adenocarcinoma and its correlation with clinicopathological features and prognosis
por: Jia, Shengnan, et al.
Publicado: (2018)

High expression of syndecan-4 is related to clinicopathological features and poor prognosis of pancreatic adenocarcinoma
por: Zhu, Yufei, et al.
Publicado: (2022)

Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma
por: Suzuoki, M, et al.
Publicado: (2002)

Clinical impacts of resection margin status and clinicopathologic parameters on pancreatic ductal adenocarcinoma
por: Jamiyan, Tsengelmaa, et al.
Publicado: (2020)

Diabetes Mellitus and Pancreatic Ductal Adenocarcinoma—Prevalence, Clinicopathological Variables, and Clinical Outcomes
por: Badowska-Kozakiewicz, Anna, et al.
Publicado: (2022)

Clinicopathological and Prognostic Value of Survivin Expression in Surgically Resected Pancreatic Ductal Adenocarcinoma
por: Vay, Christian, et al.
Publicado: (2022)

New Morphological Features for Grading Pancreatic Ductal Adenocarcinomas
por: Song, Jae-Won, et al.
Publicado: (2013)

Immune features of the peritumoral stroma in pancreatic ductal adenocarcinoma
por: Ahmed, Azaz, et al.
Publicado: (2022)

Corrigendum: Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma
por: Yang, Jian-Yu, et al.
Publicado: (2015)

Clinicopathological implications of NQO1 overexpression in the prognosis of pancreatic adenocarcinoma
por: Ji, Meiying, et al.
Publicado: (2017)

Elevated glypican‐1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma
por: Lu, Haizhen, et al.
Publicado: (2017)

Utilization of CDX2 Expression in Diagnosing Pancreatic Ductal Adenocarcinoma and Predicting Prognosis
por: Xiao, Wenbin, et al.
Publicado: (2014)

Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis
por: Wang, Jin-Dao, et al.
Publicado: (2016)

Surgical Treatment of Pancreatic Ductal Adenocarcinoma
por: Wei, Kongyuan, et al.
Publicado: (2021)

Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma
por: Saukkonen, Kapo, et al.
Publicado: (2015)

Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma
por: Lohneis, Philipp, et al.
Publicado: (2018)

The effects of systemic inflammatory response on prognosis of pancreatic ductal adenocarcinoma
por: Aktekin, Ali, et al.
Publicado: (2019)

Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

PRSS1 genotype is associated with prognosis in patients with pancreatic ductal adenocarcinoma
por: Wu, Huasheng, et al.
Publicado: (2020)

Perineural Invasion and TAMs in Pancreatic Ductal Adenocarcinomas: Review of the Original Pathology Reports Using Immunohistochemical Enhancement and Relationships with Clinicopathological Features
por: Zeng, Linjuan, et al.
Publicado: (2014)

Comparative Analyses of the Clinicopathologic Features of Short-Term and Long-Term Survivors of Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreatoduodenectomy
por: Liang, Tom Z., et al.
Publicado: (2023)

Clinicopathological characteristics and prognosis of triple-negative breast cancer invasive ductal carcinoma with ductal carcinoma in situ
por: Liu, Yang, et al.
Publicado: (2023)

Prorenin receptor acts as a potential molecular target for pancreatic ductal adenocarcinoma diagnosis
por: Arundhathi, Arivajiagane, et al.
Publicado: (2016)

Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma
por: Wang, Weijia, et al.
Publicado: (2021)

Pancreatic and duodenal homeobox-1 in pancreatic ductal adenocarcinoma and diabetes mellitus
por: Tang, Zhen-Chu, et al.
Publicado: (2020)

Methylation of CALCA and CALCB in Pancreatic Ductal Adenocarcinoma
por: Gao, Feng, et al.
Publicado: (2021)

Up-Regulated MISP Is Associated With Poor Prognosis and Immune Infiltration in Pancreatic Ductal Adenocarcinoma
por: Huang, Xinyang, et al.
Publicado: (2022)

The Impact of Immune Microenvironment on the Prognosis of Pancreatic Ductal Adenocarcinoma Based on Multi-Omics Analysis
por: Yang, Bing, et al.
Publicado: (2021)

CXCR4-A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis
por: Krieg, Andreas, et al.
Publicado: (2015)

High levels of serum glypican‐1 indicate poor prognosis in pancreatic ductal adenocarcinoma
por: Zhou, Cong‐ya, et al.
Publicado: (2018)

Development and validation of glycolysis‐related prognostic score for prediction of prognosis and chemosensitivity of pancreatic ductal adenocarcinoma
por: Zhang, Xiu‐Ping, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gergin9brmqalloeago7084a2s